Another recent study explored the combination between venetoclax and the MEK inhibitor cobimetinib or MDM2 inhibitor idasanutlin in patients with relapsed or refractory AML (Table 2) [97]. This evidence concerns the gene MDM2 and acute myeloid leukemia.